Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on IDT Australia.
RELATED STOCKHEAD STORIES
News
Closing Bell: ASX retreats, led by 2pc drop in energy
Health & Biotech
Dr Boreham’s Crucible: The reality of IDT Australia actually getting a COVID vaccine in a vial
News
August ASX Winners Column: Reporting season failed to get investors excited, but coal, lithium and COVID battlers did
Health & Biotech
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
News
Weed Week: Cannabis trade shows and Europe imports medicinal marijuana
Health & Biotech
ASX Health Stocks: Dimerix commences Phase 3 trial, while IDT scoots 10pc after restoring profit
News
Rise and Shine: What you need to know before the ASX opens
News
ASX Small Cap Lunch Wrap: Who’s playing ‘follow the leader’ today?
Health & Biotech
ASX Health Stocks: IDT shoots 20pc on COVID-19 deal with government, ImpediMed granted US FDA Breakthrough
News
10 at 10: These ASX stocks are the first to shine this morning
Guides
ASX Cannabis Stocks Guide 2021: Here’s everything you need to know
News
Weed Week: Cannabis business degrees, cornering Germany’s €200M market and Hanks Kerchiefs hits stores
Health & Biotech
Investors have struggled to find long term money makers from COVID, but has this sector been the one all along?
Health & Biotech
Hot Pot Stocks: Here are 8 ASX plays that have tripled in the last 12 months
Health & Biotech
Weed Week: 4/20 can’t help ASX cannabis companies
Health & Biotech
AstraZeneca rollout in jeopardy? The ASX’s COVID vaccine maker and wannabe seem immune
Health & Biotech
